Selank (Russian-developed tuftsin analog)
Heptapeptide anxiolytic analog of tuftsin
At a glance
What it is: Heptapeptide anxiolytic analog of tuftsin.
Primary research applications:
- Approved in Russia: generalized anxiety disorder
- Off-label: anxiety and cognitive effects
Editorial summary: Selank is a Russian-approved anxiolytic peptide with small clinical trials comparing favorably to benzodiazepines. Western-language evidence is limited. Unlike benzodiazepines, its mechanism appears more GABAergic-modulating than GABAergic-agonist.
What is Selank?
Selank is a synthetic heptapeptide analog of tuftsin, a naturally occurring immunomodulatory peptide. Developed in Russia in the 1990s and approved there as a nasal anxiolytic.[1]
Mechanism of action
Proposed mechanisms include modulation of GABA and serotonin systems, upregulation of BDNF, and peripheral immune effects. Unlike classic anxiolytics, Selank does not produce sedation, physical dependence, or withdrawal in available reports.
What the research shows
The peer-reviewed literature on Selank is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces anxiety without sedation or dependence | Russian clinical trials | Supported |
| Works intranasally | Approved nasal spray formulation | Supported |
| Enhances cognition in healthy adults | Subjective reports; limited controlled evidence | Preliminary |
Reported user experiences
How the research describes administration
Intranasal spray is the approved format in Russia. Grey-market users sometimes also inject, which is not an approved route.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Selank is one of the more intriguing grey-market peptides for anxiety: real Russian clinical trial history, plausible mechanism, favorable acute tolerability. The gap is independent Western validation.
Frequently asked questions
Is Selank like a benzodiazepine?
It has anxiolytic effects without producing sedation or dependence, so the acute user experience is different. Mechanism appears partly GABAergic but through modulation rather than direct receptor agonism.
Is Selank approved in the US?
No — only in Russia.
References
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide selank on a conditioned active avoidance reflex. Neurosci Behav Physiol. 2003;33(1):17-21. https://pubmed.ncbi.nlm.nih.gov/12617305/
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. https://pubmed.ncbi.nlm.nih.gov/18454071/